Simlukafusp alfa (FAP-IL2v) plus atezolizumab with or without bevacizumab in unresectable, metastatic renal cell carcinoma: a randomized, open-label phase Ib study.

J Immunother Cancer · 2026 · PMC13084956 · PMID 41956546

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a nonsignificant trendno p-value reported

Baseline PD-L1 expression on tumor cells was almost undetectable in most patients, but there was a nonsignificant trend toward higher expression (≥1%) in non-responders than responders.

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.